Astra AB was founded in 1913 in Södertälje (Sweden). In 1949 the company launched a xylocaine (lidocaine active substance), a drug for local anesthesia.
In 1999, Astra AB and Zeneca Group plc merged into AstraZeneca plc with headquarters in London. In 1999, AstraZeneca has chosen a new location for its offices in the United States. They became "Fairfax-plus" in North Wilmington, Delaware.
In March 2013 AstraZeneca announced a major restructuring, including the closure of research and development center in Alderley Park, investing $ 500 million to build a new research and development center in Cambridge, and translation of corporate headquarters from London to Cambridge in 2016.
AstraZeneca leads the development, production and sale of pharmaceutical and biotechnological products, operating in the therapeutic areas such as gastroenterology, cardiology, vascular pathology, neurology, psychiatry, infectious diseases, pulmonology, oncology.
The company's headquarters is located in Cambridge (UK). Research and development centers are located in the cities of Gaithersburg (Maryland, USA), Cambridge (UK), Mölndal (Sweden).
The total number of personnel, involved in research and development, is about 9,000 people.